TY - JOUR
T1 - Locoregional recurrence in patients with HER2 positive breast cancer
AU - Brollo, Janaina
AU - Kneubil, Maximiliano Cassilha
AU - Botteri, Edoardo
AU - Rotmensz, Nicole
AU - Duso, Bruno Achutti
AU - Fumagalli, Luca
AU - Locatelli, Marzia Adelia
AU - Criscitiello, Carmen
AU - Lohsiriwat, Visnu
AU - Goldhirsch, Aron
AU - Leonardi, Maria Cristina
AU - Orecchia, Roberto
AU - Curigliano, Giuseppe
PY - 2013/1/1
Y1 - 2013/1/1
N2 - Literature shows that HER2/neu positive breast cancer cells are more sensitive to radiation-induced apoptosis by targeting the epidermal growth factor receptor family tyrosine kinase. We selected 466 patients with pT1-2 HER2/neu positive tumors who received adjuvant trastuzumab for primary invasive breast cancer. Patients were divided into three groups [Quadrantectomy followed by conventional radiotherapy vsQuadrantectomy followed by Intra-operative radiotherapy with electrons vsMastectomy without radiotherapy]. After a median follow-up of 52 months, the 5-year cumulative incidence of locoregional recurrence (LRR) was 1.9%, 11.5% and 5.0% respectively ( p<0.01). At the multivariate analysis, extensive perivascular invasion, Luminal B HER2/Progesterone Receptor (PgR) negative status and Quadrantectomy followed by Intra-operative radiotherapy with electrons have significantly increased the risk of LRR. Our results suggest that HER2/neu positive breast cancer might have better outcomes when treated simultaneously with external radiotherapy and trastuzumab. Moreover, we underline the importance of PgR and further new stratification of risk among luminal subtypes.
AB - Literature shows that HER2/neu positive breast cancer cells are more sensitive to radiation-induced apoptosis by targeting the epidermal growth factor receptor family tyrosine kinase. We selected 466 patients with pT1-2 HER2/neu positive tumors who received adjuvant trastuzumab for primary invasive breast cancer. Patients were divided into three groups [Quadrantectomy followed by conventional radiotherapy vsQuadrantectomy followed by Intra-operative radiotherapy with electrons vsMastectomy without radiotherapy]. After a median follow-up of 52 months, the 5-year cumulative incidence of locoregional recurrence (LRR) was 1.9%, 11.5% and 5.0% respectively ( p<0.01). At the multivariate analysis, extensive perivascular invasion, Luminal B HER2/Progesterone Receptor (PgR) negative status and Quadrantectomy followed by Intra-operative radiotherapy with electrons have significantly increased the risk of LRR. Our results suggest that HER2/neu positive breast cancer might have better outcomes when treated simultaneously with external radiotherapy and trastuzumab. Moreover, we underline the importance of PgR and further new stratification of risk among luminal subtypes.
KW - Breast cancer
KW - HER2/neu
KW - Locoregional recurrence
KW - Radiation therapy
KW - Trastuzumab
UR - http://www.scopus.com/inward/record.url?scp=84884140983&partnerID=8YFLogxK
U2 - 10.1016/j.breast.2013.03.010
DO - 10.1016/j.breast.2013.03.010
M3 - Article
C2 - 23642529
AN - SCOPUS:84884140983
SN - 0960-9776
VL - 22
SP - 856
EP - 862
JO - Breast
JF - Breast
IS - 5
ER -